What blood-biomarker studies reveal, and what they cannot yet establish for an individual athlete.
Can blood biomarkers guide concussion recovery?
Key takeaways
Group differences do not establish an individual diagnostic or recovery test.
Fluid biomarkers remain in the research setting.
Clinical assessment and supervised return-to-sport progression remain central to care.
Blood biomarkers can help researchers study biological changes after concussion. The studies below describe group differences and associations with brain imaging; they do not establish an individual test for diagnosis, recovery, or clearance to return to sport.
The Amsterdam consensus places fluid biomarkers and emerging technologies in the research setting. Clinical assessment and a supervised return-to-sport progression remain central to care.
Research findings and clinical decisions
Concussion assessment combines the injury history, symptoms, examination, and other clinical findings. A biomarker difference between groups does not supply a validated threshold for an individual athlete. The clinical meaning of biomarker changes that persist after symptoms resolve remains uncertain.
These related analyses address different questions. Their sample sizes should not be added together as independent evidence.
2020JAMA Network Open
Association of Blood Biomarkers With Acute Sport-Related Concussion in Collegiate Athletes
McCrea M, Broglio SP, McAllister TW, et al.
A multicenter prospective case-control study included 504 collegiate athletes: 264 with concussion, 138 contact-sport controls, and 102 non-contact controls. GFAP, UCH-L1, and tau increased acutely relative to preseason measurements; the overall NfL group-by-visit interaction was not significant.
How to interpret it: The findings describe biological responses in groups. They do not establish a stand-alone diagnostic test or a return-to-sport threshold for an individual athlete.
Funding & disclosures: NCAA and US Department of Defense CARE support. The paper reports no sponsor role in conduct or publication decisions and lists investigators’ outside relationships in its full disclosures.
2021JAMA Network Open
Assessment of Blood Biomarker Profile After Acute Concussion During Combative Training Among US Military Cadets
Giza CC, McCrea M, Huber D, et al.
A prospective case-control study compared 67 cadets with concussion and 36 controls from combative training at two service academies. GFAP and UCH-L1 were elevated acutely; GFAP remained higher at 24–48 hours and after symptom resolution. Adding biomarkers did not improve discrimination beyond SCAT-3 symptom scores.
How to interpret it: Small groups, limited preinjury samples, and baseline differences constrain interpretation. Persistent biomarker differences do not, by themselves, establish unsafe return to activity or a recovery threshold.
Funding & disclosures: NCAA and US Department of Defense CARE support. The full paper reports funder roles and investigators’ outside relationships, including Giza’s Highmark Interactive fees and stock options.
2023Neurology
Longitudinal Associations Between Blood Biomarkers and White-Matter MRI in Sport-Related Concussion
Wu YC, Wen Q, Thukral R, et al.
Researchers analyzed blood and diffusion MRI data from 77 collegiate athletes with concussion at 24–48 hours, symptom resolution, and seven days after return to play. Total tau showed the strongest associations with white-matter diffusion measurements. Early-tau associations with later MRI measurements did not remain significant after correction for multiple comparisons.
How to interpret it: This analysis linked research measurements without direct control-group comparisons or clinical-assessment correlations. It did not validate clinical recovery or return-to-sport readiness.
Funding & disclosures: NCAA/DoD CARE and NIH support. The published statement reports no relevant disclosures and links to full author disclosures.
HERO Lab’s research questions
HERO Lab is investigating whether wearable HRV measurements and oculomotor testing can add information about recovery alongside established clinical assessments. The blood-biomarker studies above do not validate WHOOP or EyeSync for clearance decisions.
Our AMSSM 2026 resistance-exercise presentation describes a separate, preliminary observational study of 11 athletes. Its uncontrolled design cannot establish safety or faster recovery.
Want to get involved?
Ask the research team about current concussion studies and eligibility. Researchers and partners can also contact HERO Lab about collaboration.